H.C. Wainwright initiated coverage of ADMA Biologics (NASDAQ:ADMA) with a “buy” rating and $17 price target. The stock closed at $5.03 on Oct. 29. Since its IPO in 2013, the company’s focus has been on bringing a...
Leerink launched coverage of Inspire Medical Systems (NYSE:INSP) with an “outperform” rating and $57 price target. The stock closed at $40 on Oct. 26. “We see Inspire as a sustainable ultra high-growth/gross margin...
Stifel initiated coverage of IRIDEX (NASDAQ:IRIX) with a “buy” rating and price target of $9. The stock closed at $5.40 on Oct. 25. IRIDEX is a leader in developing, manufacturing, and marketing laser-based medical...
Ladenburg Thalmann launched coverage of Athenex (NASDAQ:ATNX) with a “buy” rating and $27 price target. The stock closed at $12.37 on Oct. 24. Athenex is focused on the development and commercialization of novel...
H.C. Wainwright initiated coverage of Autolus Therapeutics (NASDAQ:AUTL) with a “buy” rating and $45 price target. The stock closed at $30.64 on Oct. 23. Autolus is a UK-based, oncology-focused, autologous cell therapy...
BTIG launched coverage of Gritstone Oncology (NASDAQ:GRTS) with a “buy” rating and $26 price target. The stock closed at $15.17 on Oct. 22. Gritstone is a clinical-phase oncology company that specializes in focusing a...
IntelGenx Technologies (TSXV:IGX; OTCQX:IGXT)completed an offering of 17,144,314 units at a price of 70 (U.S.) cents each for gross proceeds of approximately $12-million. Each unit consists of one common share of...
Piper Jaffray initiated coverage of Ra Medical Systems (NASDAQ:RMED) with an “overweight” rating and price target of $23. The stock closed at $13.25 on Oct. 19. Ra makes and sells excimer laser products. While it has a...
Shares of Titan Pharmaceuticals (NASDAQ:TTNP) jumped 33% to close at 32 cents on Oct. 18 after A.G.P./Alliance Global Partners initiated coverage of Titan with a “buy” rating and price target of 45 cents. Turnover was a...
BTIG launched coverage of Y-mAbs Therapeutics (NASDAQ:YMAB) with a “buy” rating and $35 price target. The stock closed at $21.60 on Oct. 15. Y-mAbs is in pivotal trials for the treatment of both primary neuroblastomas...